tiprankstipranks
Altamira Therapeutics Reports Narrowed Losses
PremiumCompany AnnouncementsAltamira Therapeutics Reports Narrowed Losses
5M ago
Altamira Therapeutics reports 1H EPS ($2.11) vs. ($21.55) last year
Premium
The Fly
Altamira Therapeutics reports 1H EPS ($2.11) vs. ($21.55) last year
5M ago
Altamira Therapeutics sees FY24 total cash needs $5.8M-$7M
Premium
The Fly
Altamira Therapeutics sees FY24 total cash needs $5.8M-$7M
5M ago
Altamira Therapeutics files to sell common stock, warrants, no amount given
PremiumThe FlyAltamira Therapeutics files to sell common stock, warrants, no amount given
6M ago
Altamira Therapeutics announces confirmed suitability of Bentrio for athletes
Premium
The Fly
Altamira Therapeutics announces confirmed suitability of Bentrio for athletes
7M ago
Altamira Therapeutics announces publication of article on Zbtb46 mRNA
Premium
The Fly
Altamira Therapeutics announces publication of article on Zbtb46 mRNA
7M ago
Altamira Therapeutics files provisional patent application for OligoPhore
PremiumThe FlyAltamira Therapeutics files provisional patent application for OligoPhore
10M ago
Altamira Therapeutics announces publication of results from Bentrio trial
Premium
The Fly
Altamira Therapeutics announces publication of results from Bentrio trial
10M ago
Altamira Therapeutics Announces 2024 Annual Meeting
Premium
Company Announcements
Altamira Therapeutics Announces 2024 Annual Meeting
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100